BRPI1015338C1 - formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento - Google Patents

formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Info

Publication number
BRPI1015338C1
BRPI1015338C1 BRPI1015338A BRPI1015338A BRPI1015338C1 BR PI1015338 C1 BRPI1015338 C1 BR PI1015338C1 BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 C1 BRPI1015338 C1 BR PI1015338C1
Authority
BR
Brazil
Prior art keywords
salt
compound
drip
aggregate
pharmaceutical formulation
Prior art date
Application number
BRPI1015338A
Other languages
English (en)
Inventor
Lopez De Diego Heidi
Treppendahl Svend
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015338(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BRPI1015338A2 publication Critical patent/BRPI1015338A2/pt
Publication of BRPI1015338B1 publication Critical patent/BRPI1015338B1/pt
Publication of BRPI1015338B8 publication Critical patent/BRPI1015338B8/pt
Publication of BRPI1015338C1 publication Critical patent/BRPI1015338C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)

Abstract

formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento proporciona-se formulações líquidas de sais de adição de ácido láctico de 1-[2,4-dimetilfenilsulfanil)-fenil]piperazina.
BRPI1015338A 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento BRPI1015338C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900531 2009-04-24
DKPA200900531 2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en) 2009-04-24 2010-04-16 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (4)

Publication Number Publication Date
BRPI1015338A2 BRPI1015338A2 (pt) 2016-05-31
BRPI1015338B1 BRPI1015338B1 (pt) 2021-01-05
BRPI1015338B8 BRPI1015338B8 (pt) 2021-05-25
BRPI1015338C1 true BRPI1015338C1 (pt) 2021-08-10

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015338A BRPI1015338C1 (pt) 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Country Status (35)

Country Link
US (4) US8940746B2 (pt)
EP (1) EP2421534B1 (pt)
JP (1) JP5722879B2 (pt)
KR (1) KR101779214B1 (pt)
CN (2) CN104693145A (pt)
AR (2) AR076400A1 (pt)
AU (1) AU2010238946B2 (pt)
BR (1) BRPI1015338C1 (pt)
CA (1) CA2759456C (pt)
CL (1) CL2011002631A1 (pt)
CO (1) CO6450649A2 (pt)
CR (1) CR20110554A (pt)
DK (1) DK2421534T3 (pt)
DO (2) DOP2011000319A (pt)
EA (1) EA021122B1 (pt)
ES (1) ES2512719T3 (pt)
GE (1) GEP20135938B (pt)
HK (1) HK1206732A1 (pt)
HR (1) HRP20140880T1 (pt)
IL (1) IL215362A0 (pt)
MA (1) MA33298B1 (pt)
MX (1) MX2011011119A (pt)
MY (1) MY155288A (pt)
NZ (1) NZ596431A (pt)
PL (1) PL2421534T3 (pt)
PT (1) PT2421534E (pt)
RS (1) RS53539B1 (pt)
SG (1) SG175124A1 (pt)
SI (1) SI2421534T1 (pt)
SM (1) SMT201400159B (pt)
TN (1) TN2011000504A1 (pt)
TW (1) TWI461224B (pt)
UA (1) UA106985C2 (pt)
WO (1) WO2010121621A1 (pt)
ZA (1) ZA201107731B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53539B1 (sr) 2009-04-24 2015-02-27 H. Lundbeck A/S Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
AU2014286308B2 (en) * 2013-07-01 2018-05-10 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
BR112017021277A2 (pt) 2016-02-08 2018-06-26 H Lundbeck As Síntese de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7874549B2 (ja) 2020-04-03 2026-06-16 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
EP4681702A1 (en) * 2024-07-16 2026-01-21 PharmaPath S.A. Oral solution comprising vortioxetine hydrobromide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2004087156A1 (en) 2003-04-04 2004-10-14 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
MX2008016008A (es) 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
RS53539B1 (sr) 2009-04-24 2015-02-27 H. Lundbeck A/S Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina

Also Published As

Publication number Publication date
DK2421534T3 (da) 2014-10-13
EA021122B1 (ru) 2015-04-30
CA2759456C (en) 2017-10-31
EP2421534A1 (en) 2012-02-29
IL215362A0 (en) 2011-12-29
BRPI1015338B1 (pt) 2021-01-05
US20150094316A1 (en) 2015-04-02
MY155288A (en) 2015-09-30
JP2012524735A (ja) 2012-10-18
KR101779214B1 (ko) 2017-09-18
TN2011000504A1 (en) 2013-05-24
TW201041604A (en) 2010-12-01
SG175124A1 (en) 2011-12-29
US10857149B2 (en) 2020-12-08
CA2759456A1 (en) 2010-10-28
KR20120022809A (ko) 2012-03-12
CL2011002631A1 (es) 2012-04-09
CO6450649A2 (es) 2012-05-31
HK1206732A1 (en) 2016-01-15
US8940746B2 (en) 2015-01-27
RS53539B1 (sr) 2015-02-27
CN102405048A (zh) 2012-04-04
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
DOP2011000319A (es) 2012-02-29
MA33298B1 (fr) 2012-05-02
US20170224677A1 (en) 2017-08-10
TWI461224B (zh) 2014-11-21
ES2512719T3 (es) 2014-10-24
MX2011011119A (es) 2011-11-04
EA201171287A1 (ru) 2012-04-30
SI2421534T1 (sl) 2014-11-28
US20120035188A1 (en) 2012-02-09
PL2421534T3 (pl) 2014-12-31
PT2421534E (pt) 2014-10-29
JP5722879B2 (ja) 2015-05-27
AU2010238946B2 (en) 2013-03-28
HRP20140880T1 (hr) 2014-11-07
US10034876B2 (en) 2018-07-31
BRPI1015338B8 (pt) 2021-05-25
NZ596431A (en) 2012-12-21
AR076400A1 (es) 2011-06-08
DOP2012000211A (es) 2013-03-31
BRPI1015338A2 (pt) 2016-05-31
US20190167667A1 (en) 2019-06-06
CN104693145A (zh) 2015-06-10
WO2010121621A1 (en) 2010-10-28
AU2010238946A1 (en) 2011-12-08
AR122051A2 (es) 2022-08-10
GEP20135938B (en) 2013-10-10
US9475748B2 (en) 2016-10-25
UA106985C2 (uk) 2014-11-10
ZA201107731B (en) 2013-02-27
SMT201400159B (it) 2015-01-15

Similar Documents

Publication Publication Date Title
BRPI1015338B8 (pt) formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento
PE20150998A1 (es) Inhibidores de histona demetilasas
MX2011012344A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo.
BRPI1013237A2 (pt) formulação aquosa estável, estéril, forma de dosagem unitária farmacêutica, recipiente vedado, kit, métodos para tratar um distúrbio ou doença de células b em um humano, para esgotar células b que expressam cd-19 em um paciente humano, e para intensificar a estabilidade de armazenamento de uma formulação aquosa, e, processo para preparar uma formulação
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
BRPI0820471A2 (pt) Derivados de 1,2,3-triazol para uso como inibidores de estearoil-coa dessaturase
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
BRPI0820438A2 (pt) Composição radiofarmacêutica estabilizada, método para a preparação da mesma, e, uso de ácido gentísico ou um sal do mesmo com um cátion biocompatível.
WO2013063357A3 (en) Salts of carboxylic acid herbicides
BR112012003138A2 (pt) sal de adição de ácido de lenalidomida, processos para preparar um sal de adição de ácido de lenalidomida, e para purificar base de lenalidomina, composição farmacêutica, e, uso de sais de adição de ácido e/ou da composição.
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
BR112014009165A2 (pt) sal e uso médico
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
CL2013002996A1 (es) Uso de aclidinio o sus sales o cualquiera de sus estereoisomeros o mezcla de estereoisomeros, o una sal farmeceuticamente aceptable o solvato del mismo para la preparacion de un medicemnto util en mejorar la calidad del sueño en enfermos respiratorios.
PE20211391A1 (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico
CL2013000085A1 (es) Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.
BR112012000410A2 (pt) uso de benzidamina ou dos sais de adição de ácido, método para o tratamento de uma doença, e, composição farmacêutica
ECSP088088A (es) Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas
GB201004677D0 (en) New salt
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.
BR112015005489A2 (pt) composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas
CY1115793T1 (el) Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
TH133984A (th) เกลือไดแซคคาริน, กรดไดฟูมาริก, กรดได-1-ไฮดรอกซี-2-แนพโทอิกหรือกรดโมโน-เบนโซอิกของ 4-(ไดเมทิลอะมิโน)บิวทิล 2-(4-((2-อะมิโน-4-เมทิล-6-(เพนทิลอะมิโน)ไพริมิดิน-5-อิล)เมทิล)ฟีนิล)อะซิเตท
PL406517A1 (pl) Zastosowanie kwasu kynureninowego i jego soli oraz kompozycja farmaceutyczna

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO A QUALIFICACAO DO TITULAR.